4-(5-methyl-furfuryl)-morpholine | 118521-83-8

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 4-(5-methyl-furfuryl)-morpholine
• 英文别名: 4-(5-Methyl-furfuryl)-morpholin；Cambridge id 5513744；4-[(5-methylfuran-2-yl)methyl]morpholine
• CAS: 118521-83-8
• 化学式: C₁₀H₁₅NO₂
• 分子量: 181.235
• InChiKey: HVXXKMUPTZYRPD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  13
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  25.6
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为产物：
  描述：

  双吗啉甲烷 在 乙酰氯 作用下， 以 乙醚 、 乙腈 为溶剂， 反应 72.0h， 生成 4-(5-methyl-furfuryl)-morpholine
  参考文献：
  名称：

  Mannich reactions of furan and 2-methylfuran using pre-formed imonium salts

  摘要：

  DOI：

  10.1016/s0040-4039(00)86064-5

文献信息

• [EN] DIACYLGLYCEROL KINASE MODULATING COMPOUNDS<br/>[FR] COMPOSÉS MODULANT LA DIACYLGLYCÉROL KINASE
  申请人：CARNA BIOSCIENCES INC

  公开号：WO2021130638A1

  公开（公告）日：2021-07-01

  The present disclosure provides diacylglycerol kinase modulating compounds, and pharmaceutical compositions thereof, for treating cancer, including solid tumors, and viral infections, such as HIV or hepatitis B virus infection. The compounds can be used alone or in combination with other agents.

  本公开提供了调节二酰基甘油激酶的化合物以及用于治疗癌症（包括实体瘤）和病毒感染（如HIV或乙型肝炎病毒感染）的药物组合物。这些化合物可以单独使用或与其他药物联合使用。
• [EN] 3,4-DISUBSTITUTED PYRAZOLES AS CYCLIN DEPENDENT KINASES (CDK) OR AURORA KINASE OR GLYCOGEN SYNTHASE 3 (GSK-3) INHIBITORS<br/>[FR] PYRAZOLES 3,4-DISUBSTITUTES SERVANT D'INHIBITEURS DE KINASES CYCLINES DEPENDANTES (CDK), OU DE KINASES AURORA OU DE GLYCOGENE SYNTASES 3 (GSK-3)
  申请人：ASTEX TECHNOLOGY LTD

  公开号：WO2006003440A1

  公开（公告）日：2006-01-12

  The invention provides compounds of the formula (I); or salts or solvates or N-oxides thereof; wherein: Rq is selected from groups (a), (b) and (c); the asterisk denoting the point of attachment to the pyrazole ring; X is N or CR5; X' is NR4', O, S or S(O); A is a bond or -(CH2)m-(B)n-; B is C=O, NRg(C=O) or O(C=O) wherein Rg is hydrogen or C1-4 hydrocarbyl optionally substituted by hydroxy or C1-4 alkoxy; m is 0, 1 or 2; n is 0 or 1; R0 is hydrogen or, together with NRg when present, forms a group -(CH2)p- wherein p is 2 to 4; and R1 to R6b are as defined in the description. Compounds of the formula (I) have activity as inhibitors of CDK, aurora and GSK-3 kinases are useful in treating or preventing diseases such as cancers that are mediated by the said kinases.

  本发明提供式(I)的化合物；或其盐、溶剂化物或N-氧化物；其中：Rq选自基团(a)、(b)和(c)；星号表示与吡唑环的连接点；X为N或CR5；X'为NR4'、O、S或S(O)；A为键或-(CH2)m-(B)n-；B为C=O、NRg(C=O)或O(C=O)，其中Rg为氢或C1-4烃基，可选择性地被羟基或C1-4烷氧基取代；m为0、1或2；n为0或1；R0为氢，或与存在的NRg一起形成基团-(CH2)p-，其中p为2至4；R1至R6b如说明书中所定义。式(I)的化合物作为CDK、aurora和GSK-3激酶的抑制剂，对于治疗或预防由所述激酶介导的疾病，如癌症，具有用途。
• COELENTERAZINE ANALOGUES
  申请人：PROMEGA CORPORATION

  公开号：US20170233789A1

  公开（公告）日：2017-08-17

  Described are coelenterazine analogues, methods for making the analogues, kits comprising the analogues, and methods of using the compounds for the detection of luminescence in luciferase-based assays.

  本发明涉及荧光素类似物，制备该类似物的方法，包含该类似物的试剂盒，以及使用该化合物进行基于荧光素酶的检测中发光的方法。
• Pharmaceutical compounds
  申请人：Berdini Valerio

  公开号：US20070105900A1

  公开（公告）日：2007-05-10

  The invention provides compounds of the formula (I): The compounds have activity against cyclin dependent kinases, glycogen synthase kinase and Auroa kinases and are therefore useful to treat cancer and viral diseases.

  该发明提供了化合物(I)的公式：这些化合物对于细胞周期蛋白依赖性激酶、糖原合成酶激酶和Auroa激酶具有活性，因此可用于治疗癌症和病毒性疾病。
• Pharmaceutical Compounds
  申请人：Curry Jayne Elizabeth

  公开号：US20090036435A1

  公开（公告）日：2009-02-05

  The invention provides a combination of an ancillary agent and a compound having the formula (0): or salts or tautomers or N-oxides or solvates thereof; wherein the ancillary agent is selected from: a monoclonal antibody, an alkylating agent, an anticancer agent, a further CDK inhibitor and a hormone, hormone agonist, hormone antagonist or hormone modulating agent; X is a group R 1 -A-NR 4 — or a 5- or 6-membered carbocyclic or heterocyclic ring; A is a bond, SO 2 , C═O, NR 9 (C═O) or 0(C═O) wherein R 9 is hydrogen or Ĉhydrocarbyl optionally substituted by hydroxy or C 1-4 alkoxy; Y is a bond or an alkylene chain of 1, 2 or 3 carbon atoms in length; R 1 is hydrogen; a carbocyclic or heterocyclic group having from 3 to 12 ring members; or a C 1-8 hydrocarbyl group optionally substituted by one or more substituents selected from halogen (e.g. fluorine), hydroxy, Ĉhydrocarbyloxy, amino, mono- or di-C 1-4 hydrocarbylamino, and carbocyclic or heterocyclic groups having from 3 to 12 ring members, and wherein 1 or 2 of the carbon atoms of the hydrocarbyl group may optionally be replaced by an atom or group selected from O, S, NH, SO, SO 2 ; R 2 is hydrogen; halogen; Ĉalkoxy (e.g. methoxy); or a C 1-4 hydrocarbyl group optionally substituted by halogen (e.g. fluorine), hydroxyl or C 1-4 alkoxy (e.g. methoxy); R 3 is selected from hydrogen and carbocyclic and heterocyclic groups having from 3 to 12 ring members; and R 4 is hydrogen or a Ĉhydrocarbyl group optionally substituted by halogen (e.g. fluorine), hydroxyl or C 1-4 alkoxy (e.g. methoxy).

  本发明提供了一种辅助剂和具有以下式子（0）的化合物的组合物：或其盐，互变异构体，N-氧化物或溶剂化物；其中，辅助剂选自：单克隆抗体，烷基化剂，抗癌剂，进一步的CDK抑制剂和激素，激素激动剂，激素拮抗剂或激素调节剂；X为R1-A-NR4-基团或5-或6-成员的碳环或杂环；A为键，SO2，C═O，NR9（C═O）或0（C═O），其中R9为氢或Ĉ氢基烷基，可选择地被羟基或C1-4烷氧基取代；Y为键或长度为1、2或3个碳原子的烷基链；R1为氢；具有3至12个环成员的碳环或杂环基团；或C1-8烃基基团，可选择地被一个或多个取代基取代，所述取代基选自卤素（例如氟），羟基，Ĉ烃氧基，氨基，一级或二级C1-4烃基氨基和具有3至12个环成员的碳环或杂环基团，其中烃基的1或2个碳原子可选择性地被O，S，NH，SO，SO2中的一个或一组原子取代；R2为氢；卤素；Ĉ烷氧基（例如甲氧基）；或C1-4烃基基团，可选择地被卤素（例如氟），羟基或C1-4烷氧基（例如甲氧基）取代；R3选自氢和具有3至12个环成员的碳环和杂环基团；R4为氢或Ĉ烃基基团，可选择地被卤素（例如氟），羟基或C1-4烷氧基（例如甲氧基）取代。